Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions

Chen Y., Li X., Zhang J., Peng J., Huang F., Bao J.

Clinical Trial with a reported sample of 85 on Chronic Inflammation, Immune Modulation, Autoimmune Research, published in Front Immunol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Front Immunol (2025)
Reported sample size
85
Source database
Europe PMC
PMID
40777013
PMCID
PMC12328461
DOI
10.3389/fimmu.2025.1616231
Citations
6

Abstract (original English)

Background Autoimmune diseases, such as Crohn's disease (CD) and systemic lupus erythematosus (SLE), lead to progressive multi-organ damage due to immune dysregulation and chronic inflammation. Current therapies lack efficacy and safety, often failing to sustain remission. Stem cell therapy has emerged as a promising approach for immune modulation and tissue repair. This study analyzes clinical trial trends and challenges of stem cell therapy in autoimmune diseases. Methods Clinical trial data (2006-2025) were extracted from Trialtrove. Strict inclusion criteria were applied, restricting the analysis to interventional trials while excluding observational studies, non-autoimmune disease trials, and records with incomplete information. Descriptive statistics were used to analyze trial phases, disease types, geographic distribution, funding sources, therapeutic mechanisms, and stem cell sources, followed by a comparative evaluation of therapeutic efficacy, combination strategies, and safety profiles across autoimmune indications. Results Of the 1,511 global trials, 244 were included after screening and cross-referencing. Most trials (83.6%) were in Phase I-II. CD (n=85), SLE (n=36), and scleroderma (n=32) were the most studied. The U.S. and China led in trial numbers. Academic institutions funded 49.2% of trials. Key therapeutic strategies included immune modulation, tissue repair

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansAutoimmune DiseasesTreatment OutcomeStem Cell TransplantationClinical Trials as Topic

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research